A5076935635- Neurological Disorders and Treatments
- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Neurological Disease Mechanisms and Treatments
- Cholinesterase and Neurodegenerative Diseases
- Biochemical Acid Research Studies
- Tryptophan and brain disorders
- Geotechnical and Geomechanical Engineering
- Hydraulic Fracturing and Reservoir Analysis
- Computational Drug Discovery Methods
- Drilling and Well Engineering
- Schizophrenia research and treatment
- Migraine and Headache Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Functional Brain Connectivity Studies
- Mental Health and Psychiatry
- Health, Environment, Cognitive Aging
- Sphingolipid Metabolism and Signaling
- Cancer Treatment and Pharmacology
- Circadian rhythm and melatonin
- Metabolomics and Mass Spectrometry Studies
- Biochemical effects in animals
- Treatment of Major Depression
- Oil and Gas Production Techniques
- S100 Proteins and Annexins
Mental Health Research Center of Russian Academy of Medical Sciences
2015-2024
Institute of Mining
2016-2021
Russian Academy of Sciences
2001-2015
Academy of Medical Sciences
2001-2014
Novosibirsk State University
2011
Institute of Physiologically Active Compounds
2001-2003
Early recognition of the risk Alzheimer's disease (AD) onset is a global challenge that requires development reliable and affordable screening methods for wide-scale application. Proteomic studies blood plasma are particular relevance; however, currently proposed differentiating markers poorly consistent. The targeted quantitative multiple reaction monitoring (MRM) assay reported candidate biomarkers (CBs) can contribute to creation consistent marker panel. An MRM-MS analysis 149 nondepleted...
Evaluation of the efficacy and safety Prospect in treatment cognitive, behavioral mental disorders patients with vascular dementia (VSD).In a double-blind, placebo-controlled, parallel-group randomised clinical trial, 406 aged 60-85 years old diagnosis mild/moderate (10-24 on Mini-Mental State Examination (MMSE)) without signs depression (Cornell Scale for Depression Dementia (CSDD) scores ≤10) were included. At Visit 1, complaints medical history collected, vital recorded, cognitive...
Clinical guidelines «Cognitive disorders in the elderly and senile persons».
.
To study the efficacy and safety of cereton (choline alfoscerate) in treatment elderly patients with amnestic type mild cognitive impairment (aMCI), which often represents a pre-dementia (symptomatic) stage Alzheimer's disease (AD).Fifty (40 women 10 men; mean age 68,8 years) received three-month therapy dose 1200 mg/day 3 divided doses. Fifteen same again within 1 year. Immediate delayed (7-9 months after treatment) effects therapy, including those dependent on ApoE genotype were assessed...
To determine a complex of immune markers reflecting various links multicomponent inflammatory reactions in amnestic type mild cognitive impairment (aMCI) comparison with Alzheimer's disease (AD).Sixty-seven patients aMCI, aged 72 [63; 77] years, and 91 at the age 74 [68; 79] years were examined. The aMCI was diagnosed according to criteria R.S. Petersen et al. (1999) B. Dubois (2014). diagnosis AD established accordance ICD-10 NINCDS-ADRDA criteria. degree dementia severity determined by...
Background: schizophrenia-like psychosis with very late onset is one of the most common diagnostic group in age mental disorders exclude dementia and depression psychotic symptoms [1]. Geriatric psychiatrists discuss its similarity to neurodegenerative diseases risk development outcome disease. The aim was study clinical psychopathological features manifesting schizophrenia psychoses their impact on course Patients methods: 45 patients were observed, mean 70.6 ± 8.70 years. diagnosed...
Evaluation of the efficacy and safety drug Acatinol Memantine, 20 mg (once daily) in comparison with 10 (twice patients moderate to severe vascular dementia.
To evaluate the change of a number clinical and immunological parameters patients with amnestic type Mild Cognitive Impairment (aMCI) in course therapy Choline alfoscerate (α-GPC) order to develop monitoring predicting system its effectiveness people at risk for Alzheimer's disease.Thirty aMCI, aged 56 82 years (mean age 68.8±9.4 years), received α-GPC capsules 400 mg 3 times day (1200 per day) months. Therapeutic efficacy evaluation according psychometric tests scales was carried out three...
To perform therapeutic monitoring and prediction of the neurotrophic therapy efficacy in patients with amnestic type mild cognitive impairment (aMCI) a model course cerebrolysin therapy.The study involved group 19 elderly who met diagnostic criteria aMCI. All received consisting 20 intravenous infusions (30 ml 100 isotonic sodium chloride solution). assess efficacy, psychometric scales (CGI, MMSE, MoCA-test, МDRS, FAB, Clock Drawing Test, BNT, Word Recall test, delayed reproduction 10 words,...
To assess the efficacy and safety of memantal, a generic formulation memantine, in patients with moderate severe dementia due to Alzheimer's disease (AD).Thirty AD, aged from 55 84 years, were examined. Memantal was used dose 20 mg per day after titration period. Duration treatment 3 months.To end study, there positive effect as assessed by CGI. During treatment, cognitive functions different forms daily activity have improved. Significant changes behavioral symptoms noted. No adverse...
Objectives: Although people with amnestic mild cognitive impairment (aMCI) benefit from cerebrolysin treatment, some still develop dementia. The aim of the current study was to identify most informative clinical assessment tests predict therapy efficacy in aMCI subjects treated cerebrolysin. Methods: We studied patients (aMCI; n = 53) who had regular neurocognitive and psychiatric assessments were i.v. infusions 20 × 30 ml twice a year over three years period. Data analyzed using...
Determination of effectivity and safety Cereton (Choline alfoscerate, production by Sotex) 1200 mg/day in the treatment cognitive functioning disorders patients with amnestic mild impairment (aMCI) determining its influence process (after a 3 month course taking drug) months after end aMCI on change content phosphatidylcholine, sphingomyelin, ceramide-metabolite sphingolipids activity genes controlling synthesis enzymes, which control ithe metabolism sphingomyelin ceramide (sphingomyelinase...